Amedeo Smart

Free Medical Literature Service

 

Amedeo

Peptic Ulcer
  Free Subscription

Articles published in
Aliment Pharmacol Ther
    February 2026
  1. KITCHEN P, Schutte SL, Tergast TL, Maasoumy B, et al
    Altered Pathogen Spectrum of Spontaneous Bacterial Peritonitis in Patients Treated With Proton Pump Inhibitors.
    Aliment Pharmacol Ther. 2026 Feb 17. doi: 10.1111/apt.70593.
    >> Share

    January 2026
  2. GISBERT JP, Parra P, Nyssen OP
    Review Article: Classic Bismuth Quadruple Therapy for Helicobacter pylori Infection-Questions Focused on Clinical Practice.
    Aliment Pharmacol Ther. 2026 Jan 19. doi: 10.1111/apt.70535.
    >> Share

    May 2025
  3. SPINELLI I, Ianiro G
    Letter: Helicobacter pylori and Eosinophilic Oesophagitis-Lost in Definition? Authors' Reply.
    Aliment Pharmacol Ther. 2025 May 20. doi: 10.1111/apt.70204.
    >> Share

  4. CRISTOFORI F, Dargenio VN, Francavilla R
    Letter: Helicobacter pylori and Eosinophilic Oesophagitis-Lost in Definition?
    Aliment Pharmacol Ther. 2025 May 20. doi: 10.1111/apt.70179.
    >> Share

  5. KAHRILAS PJ, Keefer L, Yadlapati R, Anastasiou F, et al
    Review Article: Individualised Management of Reflux-Like Symptoms-Strategies Beyond Acid Suppression.
    Aliment Pharmacol Ther. 2025;61:1437-1446.
    >> Share

    April 2025
  6. SPINELLI I, Ianiro G
    Letter: Meta-Analysis Critique: Refining the Association Between Helicobacter pylori and Eosinophilic Oesophagitis. Authors' Reply.
    Aliment Pharmacol Ther. 2025 Apr 10. doi: 10.1111/apt.70135.
    >> Share

  7. RAHMAN H
    Letter: Meta-Analysis Critique: Refining the Association Between Helicobacter pylori and Eosinophilic Oesophagitis.
    Aliment Pharmacol Ther. 2025 Apr 10. doi: 10.1111/apt.70122.
    >> Share

  8. SHARMA P, Vaezi M, Unge P, Andersson K, et al
    Clinical Trial: Dose-Finding Study of Linaprazan Glurate, A Novel Potassium-Competitive Acid Blocker, Versus Lansoprazole for the Treatment of Erosive Oesophagitis.
    Aliment Pharmacol Ther. 2025 Apr 4. doi: 10.1111/apt.70109.
    >> Share

    March 2025
  9. SPINELLI I, Ianiro G
    Letter: Disappearing Microbe, Emerging Disease? Nuancing the Protective Effects of Helicobacter pylori Against Eosinophilic Oesophagitis. Authors' Reply.
    Aliment Pharmacol Ther. 2025 Mar 26. doi: 10.1111/apt.70099.
    >> Share

  10. EMANUELE E, Minoretti P
    Letter: Disappearing Microbe, Emerging Disease? Nuancing the Protective Effects of Helicobacter pylori Against Eosinophilic Oesophagitis.
    Aliment Pharmacol Ther. 2025 Mar 26. doi: 10.1111/apt.70075.
    >> Share

    February 2025
  11. SPINELLI I, Porcari S, Esposito C, Fusco W, et al
    Meta-Analysis: Inverse Association Between Helicobacter pylori Infection and Eosinophilic Oesophagitis.
    Aliment Pharmacol Ther. 2025 Feb 24. doi: 10.1111/apt.70042.
    >> Share

  12. MIYAHARA S, Yamashina T, Ohyama T, Banno M, et al
    Letter: Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor.
    Aliment Pharmacol Ther. 2025 Feb 14. doi: 10.1111/apt.70011.
    >> Share

  13. CHUAH KH, Mahadeva S
    Letter: Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor: Authors' Reply.
    Aliment Pharmacol Ther. 2025 Feb 14. doi: 10.1111/apt.70025.
    >> Share

    January 2025
  14. FISCHMAN M, Elias A, Klein A, Cohen Y, et al
    Chronic Use of Proton Pump Inhibitors Is Associated With Reduced 30-Day Mortality From Acute Pancreatitis.
    Aliment Pharmacol Ther. 2025 Jan 31. doi: 10.1111/apt.18523.
    >> Share

  15. TAYLOR S, Chen L, Dutt K, Boyapati R, et al
    Blood Group B May Reduce Risk of Rebleeding in Patients With Upper Gastrointestinal Haemorrhage due to Peptic Ulcer Disease.
    Aliment Pharmacol Ther. 2025 Jan 9. doi: 10.1111/apt.18485.
    >> Share

    December 2024
  16. ARMSTRONG D, Hungin AP, Kahrilas PJ, Sifrim D, et al
    Management of Patients With Refractory Reflux-Like Symptoms Despite Proton Pump Inhibitor Therapy: Evidence-Based Consensus Statements.
    Aliment Pharmacol Ther. 2024 Dec 30. doi: 10.1111/apt.18420.
    >> Share

  17. HOWDEN CW, Katz P, DeVault KR, Metz DC, et al
    Integrated Analysis of Vonoprazan Safety for Symptomatic Gastro-Oesophageal Reflux Disease or Erosive Oesophagitis.
    Aliment Pharmacol Ther. 2024 Dec 25. doi: 10.1111/apt.18458.
    >> Share

  18. SCHULZ C, Suerbaum S, Malfertheiner P
    Editorial: Helicobacter pylori Antimicrobial Susceptibility Testing-An Expanding Toolbox. Authors' Reply.
    Aliment Pharmacol Ther. 2024 Dec 6. doi: 10.1111/apt.18429.
    >> Share

  19. CHUAH KH, Loo QY, Hian WX, Khoo XH, et al
    Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor.
    Aliment Pharmacol Ther. 2024 Dec 2. doi: 10.1111/apt.18418.
    >> Share

    September 2024
  20. IDALSOAGA F, Diaz LA, Ayares G, Cabrera D, et al
    Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease-Authors' reply.
    Aliment Pharmacol Ther. 2024 Sep 2. doi: 10.1111/apt.18246.
    >> Share

  21. KOUNTOURAS J, Vardaka E, Zavos C, Chatzopoulos D, et al
    Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease.
    Aliment Pharmacol Ther. 2024 Sep 2. doi: 10.1111/apt.18220.
    >> Share

    July 2024
  22. KOUNTOURAS J, Polyzos SA, Kazakos E, Zavos C, et al
    Letter: Role of Helicobacter pylori and metabolic syndrome-related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH.
    Aliment Pharmacol Ther. 2024 Jul 30. doi: 10.1111/apt.18124.
    >> Share

  23. BANSAL SK, Bansal MB
    'Letter: Role of Helicobacter pylori and metabolic syndrome-related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH-Authors' reply.
    Aliment Pharmacol Ther. 2024 Jul 30. doi: 10.1111/apt.18182.
    >> Share

  24. BAGER P, Dahlerup JF
    Letter: Post-endoscopic management after upper gastrointestinal bleeding-Replenishment of iron loss.
    Aliment Pharmacol Ther. 2024 Jul 16. doi: 10.1111/apt.18050.
    >> Share

  25. WANG Y, Pan Y
    Letter: Reflections on the role of over-the-scope clips in high-risk upper gastrointestinal bleeding.
    Aliment Pharmacol Ther. 2024 Jul 15. doi: 10.1111/apt.18145.
    >> Share

  26. LYU C, Yang D, Xu H, He K, et al
    Letter: Reflections on the role of over-the-scope clips in high-risk upper gastrointestinal bleeding-Authors' reply.
    Aliment Pharmacol Ther. 2024 Jul 15. doi: 10.1111/apt.18173.
    >> Share

  27. YOON JS, Lee JH
    Letter: Risks of proton pump inhibitor treatment in cirrhotic patients-Authors' reply.
    Aliment Pharmacol Ther. 2024 Jul 12. doi: 10.1111/apt.18167.
    >> Share

  28. SCHEINER B, Dominik N, Mandorfer M
    Letter: Helicobacter pylori and metabolic syndrome-related von Willebrand factor and plasminogen activator inhibitor-1 activity levels for outcome prediction of advanced chronic liver disease: Authors' reply.
    Aliment Pharmacol Ther. 2024 Jul 3. doi: 10.1111/apt.18144.
    >> Share

  29. KOUNTOURAS J, Polyzos SA, Kazakos E, Papanikolaou IS, et al
    Letter: Helicobacter pylori and metabolic syndrome-related von Willebrand factor and plasminogen activator inhibitor-1 activity levels for outcome prediction of advanced chronic liver disease.
    Aliment Pharmacol Ther. 2024 Jul 3. doi: 10.1111/apt.18066.
    >> Share

    April 2024
  30. WANG J, Wen F, Zhao J
    Letter: Risks of proton pump inhibitor treatment in cirrhotic patients.
    Aliment Pharmacol Ther. 2024 Apr 21. doi: 10.1111/apt.17954.
    >> Share

    March 2024
  31. SHUNG DL, Laine L
    Review article: Upper gastrointestinal bleeding - review of current evidence and implications for management.
    Aliment Pharmacol Ther. 2024 Mar 22. doi: 10.1111/apt.17949.
    >> Share

  32. KRAUSE AJ, Yadlapati R
    Review article: Diagnosis and management of laryngopharyngeal reflux.
    Aliment Pharmacol Ther. 2024;59:616-631.
    >> Share

    February 2024
  33. YOON JS, Hong JH, Park SY, Kim SU, et al
    High-dose proton pump inhibitor treatment is associated with a higher mortality in cirrhotic patients: A multicentre study.
    Aliment Pharmacol Ther. 2024 Feb 22. doi: 10.1111/apt.17909.
    >> Share

  34. LON N, Engel S, Damholt A, Mortensen B, et al
    Bifidobacterium breve Bif195 ameliorates aspirin-induced gastric mucosal damage: A randomised, double blind, placebo-controlled crossover trial.
    Aliment Pharmacol Ther. 2024;59:341-349.
    >> Share

    August 2023
  35. GONG EJ, Jung HK, Lee B, Hong J, et al
    Proton pump inhibitor use and the risk of metachronous gastric cancer after H. pylori eradication in patients who underwent endoscopic resection for gastric neoplasms: A population-based cohort study.
    Aliment Pharmacol Ther. 2023 Aug 17. doi: 10.1111/apt.17676.
    >> Share

    July 2023
  36. WAUTERS L, Harris PR, Walker MM, Serrano CA, et al
    Letter: childhood recurrent abdominal pain is associated with increased duodenal eosinophilia independent of Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2023;58:134-136.
    >> Share

    May 2023
  37. PIOVANI D, Tsantes AG, Schunemann HJ, Bonovas S, et al
    Letter: Potassium-competitive acid blockers may increase the risk of gastric cancer after Helicobacter pylori eradication-a retrospective multicentre-cohort analysis. Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1199-1200.
    >> Share

  38. KOUNTOURAS J, Papaefthymiou A, Polyzos SA, Kazakos E, et al
    Letter: higher severe outcomes among Helicobacter pylori-related lean patients with non-alcoholic fatty liver disease and metabolic comorbidities.
    Aliment Pharmacol Ther. 2023;57:1186-1187.
    >> Share

  39. ARAI J, Hayakawa Y, Niikura R, Ihara S, et al
    Letter: Potassium-competitive acid blockers may increase the risk of gastric cancer after Helicobacter pylori eradication a retrospective multicentre-cohort analysis.
    Aliment Pharmacol Ther. 2023;57:1196-1198.
    >> Share

    April 2023
  40. HOWDEN CW, Shah S, Pendse SN, Offman E, et al
    Physiologically based pharmacokinetic modelling to predict intragastric rifabutin concentrations in the treatment of Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2023 Apr 20. doi: 10.1111/apt.17526.
    >> Share

  41. SCARPIGNATO C, Howden CW, Leifke E, Mulford DJ, et al
    A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2023 Apr 17. doi: 10.1111/apt.17510.
    >> Share

    March 2023
  42. TAILLIEU E, De Witte C, De Schepper H, Van Moerkercke W, et al
    Clinical significance and impact of gastric non-Helicobacter pylori Helicobacter species in gastric disease.
    Aliment Pharmacol Ther. 2023 Mar 28. doi: 10.1111/apt.17488.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016